4-[5-(Dimethylamino)-1-methylbenzimidazol-2-yl]butanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-[5-(Dimethylamino)-1-methylbenzimidazol-2-yl]butanoic acid
• 英文别名: 4-[5-(dimethylamino)-1-methylbenzimidazol-2-yl]butanoic acid
• 化学式: C₁₄H₁₉N₃O₂
• 分子量: 261.32
• InChiKey: RNXGVNBKFXYQRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  58.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Bendamustine Formulations
  申请人：InnoPharma, Inc.

  公开号：US20140080880A1

  公开（公告）日：2014-03-20

  A lyophilized bendamustine composition consisting of bendamustine hydrochloride, an aqueous solvent, and optionally an excipient, and a method of preparation thereof for treating a condition in a subject are provided. The aqueous solvent includes, for example, water, an acid, a base, or a salt, etc. The excipient includes at least one cryoprotectant, for example, sucrose, trehalose, mannitol, etc. A pre-lyophilization bendamustine composition is lyophilized, for example, by freezing, primary drying, annealing, secondary drying, condensed cooling and evacuation at preset temperatures to obtain the lyophilized bendamustine composition as a cake, a powder, or a solid concentrate. The lyophilized bendamustine composition is free of a non-aqueous solvent. Reconstitution is performed by mixing the lyophilized bendamustine composition with an aqueous solvent for about 30 seconds to 300 seconds. The reconstituted bendamustine product containing about 0.2 wt % to about 2.5 wt % by weight of impurities is administered to the subject in need thereof.
• US9801859B2
  申请人：——

  公开号：US9801859B2

  公开（公告）日：2017-10-31